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9 Abstract Endothelium-dependent changes in vasomotor
10 tone, whether evoked by vasoactive agents or physical
11 forces, are recognized as essential for the local hemody-
12 namic control in various normal and pathological circum-
13 stances. They are based on a complex signaling network
14 within the vascular wall. In recent years, substantial efforts
15 have been made to analyze how such signals are generated
16 and used in the endothelium-dependent control of vascular
17 smooth muscle. The underlying mechanisms vary with
18 species, age, sex, hormonal status, vascular bed studied,
19 caliber of the blood vessels, triggering stimuli, pre-existing
20 vascular tone, oxidative stress, and pathology. Such aspects
21 and many others will be addressed specifically by the
22 authors contributing to this volume.
23 Keywords Endothelium . Nitric oxide . EDHF. KCa . TRP.
24 Oxidative stress
25The endothelial saga: the past
26The endothelial saga started with Robert Furchgott [18, 61],
27who demonstrated that endothelial cells play an essential
28role in the relaxation evoked by acetylcholine in isolated
29arteries, which is mediated by activation of endothelial
30muscarinic receptors. His simple pharmacological experi-
31ments have revolutionized not only vascular pharmacology
32and physiology but science in general, as they lead to the
33discovery of the role of nitric oxide (NO) in biology [61].
34Using “sandwich” bioassay preparations (a layering of
35arterial strips with and without endothelium whereby the
36contractile responses are measured only in the strip without
37endothelium), he demonstrated that the endothelium-
38dependence of the response to acetylcholine is due to the
39diffusion of a vasodilator substance from the endothelial
40cells to the vascular smooth muscle cells [18]. Having ruled
41out prostacyclin, which is produced by endothelial cells
42[41], he called the unknown mediator “endothelium-derived
43relaxing factor” (EDRF). The existence of endothelium-
44dependent responses was rapidly confirmed in different
45laboratories around the world [see 37]. More sophisticated
46superfusion-bioassay systems permitted to apply pharma-
47cological inhibitors to either the endothelial cells or the
48effector vascular smooth muscle cells [e.g., 50]. The
49biological half-life of EDRF was found to be disappoint-
50ingly brief (in the order of seconds), making identification
51by conventional chemical techniques impossible. Early
52pharmacological studies indicated that endothelial cells
53can generate several other signals leading to endothelium-
54dependent relaxations [8]. The latter multiple signals
55(Fig. 1) eventually became known as “endothelium-derived
56hyperpolarizing factor(s)” (EDHF), which play a prominent
57role in smaller arteries and resistance vessels [7, 15]. In
58addition, it soon became obvious that, in veins [9], and in
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59 arteries as well [36], the endothelium produces “endothe-
60 lium-derived contracting factors” (EDCF), which add to the
61 difficulty of analyzing endothelium-dependent responses
62 [17, 37, 64]. More physiological stimuli than acetylcholine
63 [including physical forces (increases in shear stress), circulat-
64 ing hormones (catecholamines, vasopressin,), platelet prod-
65 ucts (serotonin, adenosine diphosphate), autacoids (histamine,
66 bradykinin), prostaglandin E4, and thrombin] were shown to
67 cause endothelium-dependent relaxations [37, 63]. Of those
68 more physiological stimuli, increases in shear stress [51]
69 explain the endothelium-dependency of flow-mediated
70 vasodilatation, a response that allows the most accurate
71 assessment of endothelial function in humans. Research in
72 the field was fostered by the fact that endothelium-
73 dependent relaxations are reduced under a number of
74 pathological conditions, including myocardial infarction
75 [32] and hypertension [31], which lead to the current
76 conviction that endothelial dysfunction precedes, or at
77 least accompanies, vascular disease and predicts the
78 occurrence of cardiovascular events [39, 63].
79 It soon appeared that EDRF, whatever its nature,
80 stimulated soluble guanylyl cyclase in vascular smooth
81muscle [28]. Soluble guanylyl cyclase catalyzes the
82formation of cyclic guanosine monophosphate (cyclic
83GMP), which in turn initiates relaxation. The demonstration
84followed that under superfusion-bioassay conditions super-
85oxide anions scavenge EDRF [21, 52]. Based on the earlier
86observation that nitric oxide (NO) activates soluble gua-
87nylyl cyclase and is scavenged by superoxide anions [42]
88and on his own work with acidified nitrite, Robert
89Furchgott proposed in 1986 that his EDRF is NO [19].
90Louis Ignarro had reached the same conclusion [27]. One
91year later, Salvador Moncada and his colleagues demon-
92strated, using a chemiluminescence technique, that, when
93cultured endothelial cells are stimulated with bradykinin,
94they indeed release NO [45]. The biology of NO was born.
95One crucial finding was that macrophages and endothelial
96cells transform the semi-essential amino acid L-arginine
97into NO and citrulline, and then inhibitors of the respon-
98sible enzymatic activity were discovered [24, 46, 48]. The
99access to inhibitors of nitric oxide synthase (NOS)
100permitted the exploration of the physiological role of NO
101in isolated tissues and organs, and in the intact organism.
102The fact that they augment arterial blood pressure in vivo
Fig. 1 EDRFs in 2009. Substances such as acetylcholine (ACh),
bradykinin (BK), and substance P (SP), through the activation of M3-
muscarinic, B2-bradykinin, and NK1-neuroknin receptor subtypes,
respectively, and agents that increase intracellular calcium, such as the
calcium ionophore A23187, release EDHFs. CaM calmodulin, COX
cyclooxygenase, EET epoxyeicosatrienoic acid, IP3 inositol trisphos-
phate, GC guanylate cyclase, NAPE N-acylphosphaticylethanolamine,
Hyperpol hyperpolarization, NOS NO synthase, O2
- superoxide
anions, PGI2 prostacyclin, P450 cytochrome P450 monooxygenase,
R receptor, X putative EDHF synthase. SR141716 is an antagonist of
the cannabinoid receptor subtype CB1. Glibenclamide (Glib) is a
selective inhibitor of ATP-sensitive potassium channels (KATP).
Tetraethylammonium (TEA) and tetrabutylammonium (TBA) are
nonspecific inhibitors of potassium channels when used at high
concentrations (>5 mM), while at lower concentrations (1–3 mM),
these drugs are selective for calcium-activated potassium channels
(KCa). Iberiotoxin (IBX) is a specific inhibitor of large conductance
KCa (BKCa). Charybdotoxin (CTX) is an inhibitor of BKCa, interme-
diate conductance KCa (IKCa), and voltage-dependent potassium
channels. Apamin is a specific inhibitor of small conductance KCa
(SKCa). Barium (Ba
2+), in the micromolar range, is a specific inhibitor
of the inward rectifier potassium channel (Kir). GAP 27 is an 11-
amino acid peptide possessing conserved sequence homology to a
portion of the second extracellular loop of connexin. 18α-
glycyrrhetinic acid (αGA), and heptanol are gap junction uncouplers
(from Vanhoutte et al., 2009. By permission)
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103 [49] implied a role for NO in cardiovascular homeostasis.
104 The use of NOS inhibitors in vivo rapidly lead to the
105 conclusion that NO not only is a key player in vasomotor
106 control but it affects almost every bodily function. The next
107 breakthrough came when Salomon Snyder and his group
108 isolated NOS from the brain [e.g., 6]. We now know that
109 there are three isoforms of the enzyme: neuronal NOS
110 (nNOS, NOS 1), inducible NOS (iNOS, NOS 2), and
111 endothelial NOS (eNOS, NOS 3). Paul Huang and
112 colleagues genetically engineered mice with deletion of
113 the eNOS gene [25]. These animals have an increased
114 arterial blood pressure, illustrating the role of NO in the
115 control of cardiovascular homeostasis.
116 The endothelial saga: the present
117 The advent of genetically modified animals and of
118 inhibitors of NOS permits the systematic exploration of
119 the role of NO in vascular health and disease, considerably
120 increasing our knowledge (Fig. 2). In a given blood vessel,
121 the level of activity of eNOS and the amounts of
122 endothelium-derived NO released are not constant. They
123 can be upregulated by chronic increases in shear stress
124 (exercise), hormones (estrogens), and diet (ω3-unsaturated
125 fatty acids or polyphenols of red wine, green tea, and dark
126 chocolate). The endothelial production of NO is reduced by
127 high glucose (diabetes) and increased oxidative stress
128 (hypertension) [see 3, 63]. NO not only affects the tone of
129 vascular smooth muscle, but also inhibits platelet aggrega-
130 tion, in synergy with endothelium-derived prostacyclin
131 [47], and the growth of the media [55]. It reduces the
132 endothelial production of endothelin-1 [62] and of
133 cyclooxygenase-derived EDCF [14]. NO inhibits the
134 expression of endothelial adhesion molecules and, thus,
135 the adhesion of platelets and white blood cells [47, 63]. It
136 modulates angiogenesis [3, 68]. The signaling cascade, in
137 particular, the role of Akt, in the phosphorylation that leads
138 to activation of eNOS is unraveled [3, 16, 29, 33]. The
139 original concept that the eNOS is a strictly Ca2+-dependent
140 enzyme, and, thus, that endothelium-dependent relaxations
141 rely entirely on an increase in intracellular Ca2+-concentra-
142 tion, has been challenged [3, 16]. Moreover, in vivo
143 responses to acetylcholine in arterioles consist of two
144 phases: (a) a rapidly conducted vasodilatation initiated by
145 a local rise in endothelial Ca2+ but independent of
146 endothelial Ca2+-signaling at remote sites and (b) a slower
147 complementary dilatation associated with a Ca2+-wave that
148 propagates along the endothelium [57]. In the mouse aorta,
149 calcium-imaging shows that only some clusters of endo-
150 thelial cells respond to acetylcholine, which represent only
151 one third of the total number of cells, but this is enough for
152 endothelium-dependent relaxation [4]. The importance of
153the caveolae for the activity of eNOS is now established
154[20, 40]. The formation of NO-metabolites constitutes a
155non-enzymatic source of activators of soluble guanylyl
156cyclase [38]. Beyond NO itself, derivatives such as nitroxyl
157(HNO) and nitrosothiols have also emerged as EDRFs and
158HNO may be as important as NO in rodent small arteries
159[2]. The binding of NO to superoxide anions, with the
160formation of peroxynitrite, is a major player in genesis of
161endothelial dysfunction [23, 30, 58, 67]. The progressive
162inability of endothelial cells, prematurely aged by the
163exposure to risk factors, to generate sufficient NO may
164well be the initial step permitting the inflammatory
165response that leads to atherosclerosis [see 63]. The most
166widely used therapeutic agents for the treatment of
167cardiovascular disease enhance the ability of the endothelial
168cells to produce NO [26, 59, 64].
Fig. 2 Possible mechanisms by which production of nitric oxide is
regulated in endothelial cells. Nitric oxide is produced through
enzymatic conversion of L-arginine by NOS (endothelial or type III,
eNOS). The transcription of this enzyme is regulated genomically by
hormones and growth factors. Stability of eNOS mRNA is modulated
by statins and hormones. eNOS enzyme activity requires calcium,
calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH),
and 5, 6, 7, 8-tetra-hydrobiopterine (BH4). Enzyme activity is
regulated by complexing to these proteins in microdomains of the
endothelial cell. Association with this complex of heat shock protein
90 (HSP90) increases enzyme activity. Stimulation of specific
receptors on the endothelial surface (R) complexed with guanine
nucleotide regulatory proteins, which are sensitive to pertussis toxin
(Gi) or insensitive to pertussis toxin (Gq), activate intracellular
pathways that modulate eNOS activity posttranslationally through
heat shock protein 90 or Akt-phosphorylation. Association of eNOS
with caveolin-1 or glycosylation of the enzyme reduces activity. A
metabolite of L-arginine, asymmetric dimethyl arginine (ADMA)
decreases production of the nitric oxide through competitive binding
to eNOS. Thus, this endogenous amine may be a risk factor for the
development of cardiovascular disease. Plus signs indicate stimula-
tion, minus signs indicate inhibition, question marks indicate those
pathways in which the regulation is unknown (from Vanhoutte et al.,
2009. By permission)
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169 We now appreciate better the importance and the
170 complexity of endothelium-dependent hyperpolarization in
171 the local control of vascular tone [7]. Although EDHF has
172 been considered to be of particular importance in smaller
173 arteries, we have to recognize that its contribution to
174 vasodilatation may be merely transient [22]. Nevertheless,
175 coordinated increases in small artery diameter occur by
176 means of flow-mediated vasodilatation (shear-stress-in-
177 duced and NO-dependent) combined with the conducted
178 vasodilatation resulting from electrotonic propagation of
179 hyperpolarization in the endothelium [56]. At the level of
180 endothelial protrusions, functional cooperation ensures the
181 EDHF-component of endothelium-dependent vasodilata-
182 tion, which is mediated by K+ released from endothelium
183 and involves endothelial KCa2.3 and KCa3.1, local intersti-
184 tial Ca2+, Ca2+-sensing receptors co-localized with KCa3.1
185 in caveolin-poor regions of endothelial cells, myo-
186 endothelial gap junctions, and the Na/K pump and Kir2.1
187 of the vascular smooth muscle [11]. Experiments in
188 dysgenic mice suggest that KCa2.3 and KCa3.1 have
189 important but different contributions to endothelium-
190 dependent vasodilatation and, thus, represent novel thera-
191 peutic targets for the treatment of hypertension [5, 66].
192 Inositol 1,4,5-endothelial trisphosphate receptors in the
193 endothelial protrusions subserve local Ca2+-release events
194 (“pulsars”), which activate the functionally co-localized
195 KCa3.1 [34]. Activators of the small and intermediate
196 conductance K channels constitute useful pharmacological
197 tools and potential new drugs for the treatment of
198 hypertension [54].
199 The Ca2+-dependent component of local vasodilation
200 obviously depends on Ca2+ influx into endothelial cells.
201 One of the most attractive candidate influx pathways has
202 been the store-operated Ca2+ entry (SOC), which could be
203 mediated by transient receptor potential (TRP) channels
204 [see 43 for a critical review]. SOC was indeed identified in
205 endothelium [1, 13], but a direct relation to NO produc-
206 tion and release is still under evaluation [4]. Non-store-
207 operated channels seem to play a more important role
208 in regulation of NO release [65]. The involvement of
209 TRPV4-channels in flow-induced endothelium-dependent
210 vasodilatation is now generally accepted [35, see also 44
211 for a review]; the mechanism requires an active CYP
212 epoxygenase and channel translocation to the cell mem-
213 brane, where it is associated with caveolin-1. Moreover,
214 the expression of caveolin-1 is required for EDHF-related
215 relaxation, by modulating the membrane location and
216 activity of TRPV4 channels and connexins, which are
217 both implicated at different steps in the EDHF-signaling
218 pathway [53]. The TRPV4 channels of both endothelial
219 and vascular smooth muscle cells are critically involved in
220 endothelium-dependent vasodilatation of mesenteric arter-
221 ies and in TRPV4-knockout mice the hypertension
222induced by NOS inhibition is greater than in wild-type
223animals [12].
224The endothelial saga: the future
225Much remains to be learned about the precise regulation of
226NO release by endothelial cells and also about the
227consequences of its perturbation within the complex chain
228of events leading to the vascular dysfunction characteristic of
229hypertension, diabetes, and atherosclerosis [64]. We still do
230not completely understand the exact role of EDHF-mediated
231responses in physiology and pathology, as we are still unable
232to selectively interfere with them in vivo [7]. We still do not
233fully comprehend the importance of EDCFs in endothelial
234dysfunction [60]. Finally, we have to unravel the complex
235interactions between the different endothelium-derived sig-
236nals. For example, in diabetic mice, hyperglycemia-induced
237changes in endothelial function are linked to COX2 and
238oxidative stress (enhanced NADPH oxidase and decreased
239SOD expression), uncoupling of eNOS, and changes in its
240expression and regulation, while EDHF-mediated vasodila-
241tation can be maintained, but with a modified profile [10].
242Whatever the future of endothelial research will yield, we
243should not forget that this extraordinary scientific saga
244started with the very simple pharmacological experiments
245of Robert Furchgott [18, 61], whose memory we honor in
246this special issue.
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